A new study examined differences in breast cancer recurrence and survival by region.
Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis.
The clear cell histologic subtype of stage I ovarian cancer is associated with a disproportionately high risk for capsule rupture during surgery compared with other histologies.
A new study found a link between posttraumatic stress disorder and ovarian cancer.
The combination of trilaciclib and chemotherapy was generally well–tolerated with promising activity in a phase II trial of patients with metastatic triple-negative breast cancer.
Pembrolizumab offers survival advantages at a much lower cost over atezolizumab.
A liquid biopsy may be able to predict the efficacy of EGFR-targeted tyrosine kinase inhibitors in patients with non–small cell lung cancer.
A new combination may offer better survival for patients with BRAFV600E-mutated metastatic colorectal cancer.
Extensive lymph node dissection with complete mesocolic excision resulted in significantly improved recurrence and survival outcomes in colon cancer.
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.